Biogen Inc. (BIIB)

295.61 +12.65 (+4.47%) At close: 4:00PM EDT

Biogen Inc.

225 Binney Street
Cambridge, MA 02142
United States
617-679-2000
http://www.biogen.com

Sector: Healthcare
Industry: Biotechnology
Full Time Employees: 7,400

Key Executives

Name	Title	Pay	Exercised	Age
Mr. Michel Vounatsos	CEO & Director	2.65M	N/A	55
Dr. Michael D. Ehlers M.D., Ph.D.	Exec. VP and Head of R&D	2.1M	N/A	48
Mr. Gregory F. Covino	Interim Principal Financial Officer, Chief Accounting Officer and VP of Fin.	N/A	N/A	51
Mr. Matthew Calistri	Sr. Director of Investor Relations	N/A	N/A	N/A
Ms. Susan H. Alexander Esq.	Chief of Legal & Corp. Services, Exec. VP and Corp. Sec.	N/A	N/A	60

Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Biogen Inc., a biopharmaceutical company, discovers, develops, manufactures, and delivers therapies for the treatment of neurological and autoimmune diseases worldwide. The company offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA, and FAMPYRA to treat multiple sclerosis (MS); FUMADERM for the treatment of plaque psoriasis; and SPINRAZA to treat spinal muscular atrophy. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; FLIXABI, an infliximab biosimilar referencing REMICADE; RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), and other conditions; GAZYVA to treat CLL and follicular lymphoma; and other potential anti-CD20 therapies. The company’s Phase III clinical trial products comprise GAZYVA for the treatment of front-line indolent non-hodgkin’s lymphoma; and Aducanumab and E2609 for Alzheimer’s disease. Its Phase II clinical trial products include BIIB074 for trigeminal neuralgia, lumbosacral radiculopathy, and erythromelalgia; BAN2401 for Alzheimer's disease; Opicinumab (anti-LINGO-1) for MS; TYSABRI for acute ischemic stroke; rAAV-XLRS for X-linked juvenile retinoschisis; BG00011 (STX-100) for idiopathic pulmonary fibrosis; and Dapirolizumab pegol and BIIB059 (Anti-BDCA02) for lupus. The company’s Phase I clinical trial products comprise BIIB061 for MS; BIIB054 for Parkinson's disease; BIIB067 (IONIS-SOD1Rx) for amyotrophic lateral sclerosis; and BIIB068 (BTK Inhibitor) for autoimmune disease. It has collaboration agreements with AbbVie, Inc.; Acorda Therapeutics, Inc.; Applied Genetic Technologies Corporation; Eisai Co., Ltd.; Genentech, Inc.; Ionis Pharmaceuticals, Inc.; Samsung Bioepis; and University of Pennsylvania. Biogen Inc. offers products through its sales force and marketing groups. The company was formerly known as Biogen Idec Inc. and changed its name to Biogen Inc. in March 2015. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Corporate Governance

Biogen Inc.’s ISS Governance QualityScore as of July 1, 2017 is 1. The pillar scores are Audit: 1; Board: 2; Shareholder Rights: 2; Compensation: 2.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.